8-K: NeuroBo Pharmaceuticals Receives First IRB Approval for Phase 1 Obesity Trial of DA-1726

NeuroBo Pharmaceuticals has received its first Institutional Review Board (IRB) approval to begin a Phase 1 clinical trial for its obesity treatment candidate, DA-1726.

Summary

• NeuroBo Pharmaceuticals has announced the first site Institutional Review Board (IRB) approval for its Phase 1 clinical trial of DA-1726, a dual agonist for the treatment of obesity.
• The trial will be conducted at Clinical Pharmacology of Miami, with Dr. Alexander Prezioso as the investigator.
• The company anticipates randomizing the first patient in the second quarter of 2024.
• DA-1726 is a novel oxyntomodulin (OXM) analog agonist that targets both glucagon-like peptide-1 (GLP1R) and glucagon receptors (GCGR).
• Preclinical studies in mice showed DA-1726 resulted in superior weight loss compared to semaglutide (Wegovy) and similar weight reduction to tirzepatide (Zepbound) while consuming more food.
• The Phase 1 trial is a randomized, placebo-controlled, double-blind study with two parts: a single ascending dose (SAD) study and a multiple ascending dose (MAD) study.
• The SAD study will enroll approximately 45 participants, and the MAD study will enroll approximately 36 participants.
• Top-line data from the SAD study is expected in the first half of 2025, and from the MAD study in the second half of 2025.

Sentiment

Score: 7

Explanation: The document is positive due to the achievement of a key milestone (IRB approval) and promising preclinical data. However, it also acknowledges the inherent risks in drug development, preventing a higher score.

Positives

• The first IRB approval is a significant milestone for the development of DA-1726.
• DA-1726 has shown promising results in preclinical studies, indicating potential for superior weight loss compared to existing treatments.
• The dual agonist mechanism of DA-1726 may offer a better tolerability profile than current GLP-1 agonists.
• The company has a clear timeline for the Phase 1 trial, with expected data readouts in 2025.

Risks

• The success of the clinical trial is not guaranteed, and results may not replicate preclinical findings.
• There are risks associated with the timeline for regulatory submissions and approvals.
• The company's ability to execute its commercial strategy and realize the benefits of its license agreement are subject to risks.
• There are potential risks related to the cooperation of contract manufacturers and clinical study partners.
• Negative interactions between DA-1726 and other products are a potential risk.
• The company's ability to recruit subjects for clinical trials is a risk.
• Changes in laws or regulations could impact the company.
• Changes to the company's stock price could impact the terms of the license agreement and future fundraising.

Future Outlook

The company expects to randomize the first patient in the second quarter of 2024 and report top-line data from the single ascending dose (SAD) Part 1 in the first half of 2025 and the multiple ascending dose (MAD) Part 2 in the second half of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the first site IRB approval is a significant milestone in the development of DA-1726.
• Mr. Kim also mentioned that DA-1726 may have a better tolerability profile than currently available GLP-1 agonists.

Industry Context

The announcement is relevant to the broader trend of developing new treatments for obesity, a significant global health issue. The focus on dual agonists like DA-1726 reflects the industry's pursuit of more effective and tolerable therapies compared to existing GLP-1 agonists.

Comparison to Industry Standards

• The document mentions that DA-1726 showed superior weight loss compared to semaglutide (Wegovy) in mouse models, which is a key benchmark in the obesity treatment space.
• The comparison to tirzepatide (Zepbound), another leading treatment, suggests that NeuroBo is aiming to compete with the most effective therapies currently available.
• The Phase 1 trial design, including single and multiple ascending dose studies, is standard practice for evaluating the safety and tolerability of new drug candidates.
• The use of a 6:3 randomization ratio of DA-1726 to placebo is a common approach in early-stage clinical trials.

Stakeholder Impact

• Shareholders may view the IRB approval positively, as it represents progress in the development of a potential blockbuster drug.
• Employees may be motivated by the advancement of the company's pipeline.
• Patients with obesity may benefit from the development of a new treatment option.
• The company's CRO partner and investigators will be involved in the execution of the clinical trial.

Next Steps

• The company will work with its CRO partner and investigators to start randomizing patients in the second quarter of 2024.
• The company expects to report top-line data from the single ascending dose (SAD) Part 1 in the first half of 2025.
• The company expects to report top-line data from the multiple ascending dose (MAD) Part 2 in the second half of 2025.

Key Dates

Keywords

DA-1726, obesity, clinical trial, GLP1R, GCGR, oxyntomodulin, IRB approval, Phase 1, semaglutide, weight loss, cardiometabolic, dual agonist